Gustave Roussy, Cancer Campus, Grand Paris

This study is testing if adding a highly focused, high-dose radiation treatment (called stereotactic body radiation therapy or SBRT) to standard first-line drugs can better control breast cancer that has recently spread to a few other body parts. It involves 154 patients whose ca…

This study aimed to see if giving two cancer drugs before surgery could help the immune system attack specific types of soft tissue sarcoma tumors. It focused on adults with two rare sarcoma types that had a specific immune cell pattern. The goal was to shrink tumors before remov…

This study compares two surgical approaches for low-risk thyroid cancer to determine which leads to better long-term outcomes. Patients with early-stage thyroid cancer were randomly assigned to receive either standard thyroid removal alone or thyroid removal plus additional lymph…

This study is testing a new treatment plan for a rare and aggressive form of head and neck melanoma that can be removed by surgery. The goal is to see if giving an immunotherapy drug (with or without another targeted drug) before surgery, and then continuing it after, can help ke…

This study is testing a personalized approach for patients with advanced solid tumors that have stopped responding to standard treatments. Doctors take a small sample of a patient's tumor and grow it into a 3D model in the lab. They then test different cancer drugs on this model …

This study is testing if it's safe to add a drug called regorafenib to the standard, intensive chemotherapy for Ewing sarcoma. It aims to help children and young adults (ages 2-49) whose cancer has spread to multiple parts of the body, a situation with very limited treatment opti…

This study is testing an experimental drug called DS-1062a for people with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. About 100 participants will receive the drug by IV every three weeks to see if it shrinks their tumors and…